Nemin Zhu1, Neal E Rowe2, Paul R Martin1,3, Sean S Luke1, Thomas B Mcgregor4, Frank Myslik1, Vivian C Mcalister1,3,5, Alp Sener1,3,5, Patrick P Luke1,3,5. 1. Western University Schulich School of Medicine and Dentistry, London, ON; Canada. 2. Department of Surgery, University of Ottawa, Ottawa, ON; Canada. 3. Department of Surgery, London Health Sciences Centre, Western University, London, ON; Canada. 4. Department of Surgery, Queen's University, Kingston, ON; Canada. 5. Multi-Organ Transplant Program, London Health Sciences Centre, London, ON; Canada.
Abstract
INTRODUCTION: We sought to determine whether protocol biopsies could be used to guide treatment and improve outcomes in simultaneous pancreas-kidney (SPK) patients. METHODS: Between 2004 and 2013, protocol biopsies were performed on SPK patients at 3-6 months and one year post-transplant. Maintenance immunosuppression consisted of a calcineurin inhibitor, anti-proliferative agent, and corticosteroid. Corticosteroid was withdrawn in negative early biopsies, maintained in subclinical/ borderline biopsies, and increased if Banff IB or greater rejection was identified. Endpoints included presence of interstitial fibrosis and tubular atrophy on biopsy at one year (IF/TA), rejection episodes, and renal and pancreas function at five years' followup. RESULTS: Forty-one SPK transplant patients were reviewed and a total of 75 protocol biopsies were identified. On early biopsy, 51% had negative biopsies, 44% had borderline rejection, and 5% had subclinical rejection. Renal and pancreas function were not significantly different at one, two, and five years post-transplant between negative vs. borderline early biopsy patients. No difference in the degree of IF/TA was found between these two groups. CONCLUSIONS: To our knowledge, this is the first study to evaluate protocol biopsies as an investigative tool prior to steroid withdrawal in SPK patients. Our study suggests that there are no detrimental functional or histological effects at five years post-transplant, despite weaning steroids in the negative biopsy group.
INTRODUCTION: We sought to determine whether protocol biopsies could be used to guide treatment and improve outcomes in simultaneous pancreas-kidney (SPK) patients. METHODS: Between 2004 and 2013, protocol biopsies were performed on SPK patients at 3-6 months and one year post-transplant. Maintenance immunosuppression consisted of a calcineurin inhibitor, anti-proliferative agent, and corticosteroid. Corticosteroid was withdrawn in negative early biopsies, maintained in subclinical/ borderline biopsies, and increased if Banff IB or greater rejection was identified. Endpoints included presence of interstitial fibrosis and tubular atrophy on biopsy at one year (IF/TA), rejection episodes, and renal and pancreas function at five years' followup. RESULTS: Forty-one SPK transplant patients were reviewed and a total of 75 protocol biopsies were identified. On early biopsy, 51% had negative biopsies, 44% had borderline rejection, and 5% had subclinical rejection. Renal and pancreas function were not significantly different at one, two, and five years post-transplant between negative vs. borderline early biopsy patients. No difference in the degree of IF/TA was found between these two groups. CONCLUSIONS: To our knowledge, this is the first study to evaluate protocol biopsies as an investigative tool prior to steroid withdrawal in SPK patients. Our study suggests that there are no detrimental functional or histological effects at five years post-transplant, despite weaning steroids in the negative biopsy group.
Authors: James M Gloor; Ari J Cohen; Donna J Lager; Joseph P Grande; Mary E Fidler; Jorge A Velosa; Timothy S Larson; Thomas R Schwab; Matthew D Griffin; Mikel Prieto; Scott L Nyberg; Sylvester Sterioff; Walter K Kremers; Mark D Stegall Journal: Transplantation Date: 2002-06-27 Impact factor: 4.939
Authors: Megan L Troxell; David Bradley Koslin; Douglas Norman; Stephen Rayhill; Anuja Mittalhenkle Journal: Transplantation Date: 2010-07-15 Impact factor: 4.939
Authors: Bum Soon Choi; Mi Jung Shin; Suk Joon Shin; Young Soo Kim; Yeong Jin Choi; Yong-Soo Kim; In Sung Moon; Suk Young Kim; Yong Bok Koh; Byung Kee Bang; Chul Woo Yang Journal: Am J Transplant Date: 2005-06 Impact factor: 8.086
Authors: Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Ian S D Roberts; Srikanth Reddy; Christine Russell; David R Davies; Peter J Friend; Ashok I Handa; Peter J Morris Journal: Transplantation Date: 2004-04-27 Impact factor: 4.939
Authors: D Rush; P Nickerson; J Gough; R McKenna; P Grimm; M Cheang; K Trpkov; K Solez; J Jeffery Journal: J Am Soc Nephrol Date: 1998-11 Impact factor: 10.121
Authors: Julie Ho; George N Okoli; Rasheda Rabbani; Otto L T Lam; Viraj K Reddy; Nicole Askin; Christie Rampersad; Aaron Trachtenberg; Chris Wiebe; Peter Nickerson; Ahmed M Abou-Setta Journal: Am J Transplant Date: 2021-12-10 Impact factor: 9.369